BioWorld

Sep. 21, 2006

Awaiting Genasense Decision, Genta Gets $16M In Stock Sale

The pinchpenny public market is pushing more firms to take the route of Solexa Inc., which gained a pledge for $75 million in a stock equity financing from busy Azimuth Opportunity Ltd. (BioWorld Today) Read More

Solexa Gains $75M Equity Line In Deal With Azimuth

Protease Snipping Amyloid Plaques, But Not Precursor

HELP Votes Unanimously On FDA's von Eschenbach

Clinic Roundup

Other News To Note

Appointments And Advancements

Today's news in brief

BioWorld

BioWorld briefs for Jan 23, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 23, 2026.

Illustration of human body surrounded by DNA, cell and drug icons

Cell/gene therapy sector now sustainable; China competition mounting

BioWorld

There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...

Illustration of magnifying glass inspecting brain

Neurotrimin unveiled as marker in intellectual disability

BioWorld Science

Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...

DNA mutations or genetic disorder concept art

Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease

BioWorld Science

Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...